ALX Oncology
ALXO
85 hedge funds and large institutions have $22.1M invested in ALX Oncology in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 9 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 87 → 85 (-2)
12.67% less ownership
Funds ownership: 77.87% → 65.2% (-13%)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
22% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 9
58% less call options, than puts
Call options by funds: $24K | Put options by funds: $57K
68% less capital invested
Capital invested by funds: $69M → $22.1M (-$46.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$500K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$326K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$224K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$164K |
| 5 |
AC
Almitas Capital
Santa Monica,
California
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.57M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.2M |
| 3 |
Millennium Management
New York
|
-$1.42M |
| 4 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.01M |
| 5 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$330K |
ALXO Hedge Fund Activity: Q1 2025 in Review
85 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q1 2025, worth a combined $22.1M — down 68% from $69M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ALXO and 7 opened new positions — a net loss of 2 holders — while 30 trimmed existing stakes and 26 added.
The largest buyer was Bank of America, adding an estimated $500K. The largest seller was Morgan Stanley, cutting an estimated $2.57M.
- 85 institutional investors held ALX Oncology (ALXO) as of Q1 2025, down from 87 in Q4 2024.
- Funds reported $22.1M of ALX Oncology stock for Q1 2025, down 68% quarter-over-quarter.
- 7 funds opened new ALX Oncology positions in Q1 2025 and 9 closed out, a net change of -2 holders.
- The largest ALX Oncology buyer in Q1 2025 was Bank of America, an estimated $500K added.
- The largest ALX Oncology seller in Q1 2025 was Morgan Stanley, an estimated $2.57M sold.
Based on aggregated 13F filings for Q1 2025.